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ABSTRACT 
Membrane-bound proteinase 3 (PR3m) is the 
main target antigen of anti-neutrophil 
cytoplasmic autoantibodies (ANCA) in 
granulomatosis with polyangiitis (GPA), a 
systemic small-vessel vasculitis. Binding of 
ANCA to PR3m triggers neutrophil activation 
with the secretion of enzymatically active PR3 
and related neutrophil serine proteases, thereby 
contributing to vascular damage. PR3 and 
related proteases are activated from proforms 
by the lysosomal cysteine protease cathepsin C 
(CatC) during neutrophil maturation. We 
hypothesized that pharmacological inhibition of 
CatC provides an effective measure to reduce 
PR3m and has therefore implications as a novel 
therapeutic approach in GPA. We first studied 
PR3 in neutrophils from 21 patients with 
Papillon-Lefèvre syndrome (PLS), a genetic 
form of CatC deficiency. PLS neutrophil lysates 
showed a largely reduced, but still detectable 
(0.5-4%) PR3 activity when compared to 
healthy control cells. Despite extremely low 
levels of cellular PR3, the amount of 
constitutive PR3m expressed on the surface of 
quiescent neutrophils, and the typical bimodal 
membrane distribution pattern, was similar to 
what was observed in healthy neutrophils. 
However, following cell activation, there was 
no significant increase in the total amount of 
PR3m on PLS neutrophils, whereas the total 
amount of PR3m on healthy neutrophils was 
significantly increased. We then explored the 
effect of pharmacological CatC inhibition on 
PR3 expression in normal neutrophils using a 
potent cell permeable CatC inhibitor and a 
CD34+ hematopoietic stem cell model. Human 
CD34+ hematopoietic stem cells were treated 
with the inhibitor during neutrophil 
differentiation over 10 days. We observed 
strong reductions in PR3m, cellular PR3 protein 
and proteolytic PR3 activity whereas neutrophil 
differentiation was not compromised. 
 
 
 
Granulomatosis with polyangiitis (GPA) is a 
systemic small-vessel vasculitis most 
commonly affecting the upper and lower 
respiratory tract and kidneys (1,2). The main 
target autoantigen in GPA is the neutrophil 
serine protease (NSP) proteinase 3 (PR3) (EC 
3.4.21.76) (3,4). GPA patients develop anti-
neutrophil cytoplasmic autoantibodies to PR3 
(PR3-ANCA) that bind to membrane-bound 
PR3 (PR3m) on the neutrophil surface (5,6). The 
membrane expression of PR3 is mediated by a 
hydrophobic patch at the protease surface, 
which is not conserved in other related NSPs, 
such as human neutrophil elastase (HNE), 
cathepsin G (CG) and neutrophil serine protease 
4 NSP-4 (7-9). Binding of PR3-ANCA to PR3m 
on cytokine-primed neutrophils induces cell 
activation resulting in neutrophil extracellular 
traps (NETs) production, and in granule protein 
and superoxide release (10,11). Secreted active 
proteases, including PR3 and related NSPs, 
exert proteolytic activity on endothelial cells 
thereby contributing to vascular necrosis (5,12). 
NETs are known to be directly implicated in 
ANCA induction as well as endothelial damage 
(13). There is no treatment for GPA that is based 
on disease-specific mechanisms and the current 
protocols involve combined administration of 
steroids with either cyclophosphamide or 
rituximab (14,15). These standard treatments 
are associated with toxicity highlighting the 
need to develop novel, more specific 
therapeutic strategies (16).  
Cathepsin C (CatC) (EC 3.4.14.1), also 
known as dipeptidyl peptidase I, is a lysosomal 
amino peptidase belonging to the papain 
superfamily of cysteine peptidases (17).  CatC 
catalyzes the cleavage of two residues from the 
N-termini of peptides and proteins. CatC, which 
is ubiquitously expressed in mammals is 
considered to be a major intracellular 
processing enzyme. High concentrations of 
CatC are detected in immune defense cells 
including neutrophils, mast cells, lymphocytes 
and macrophages. CatC is the physiological 
activator of several immune cell-associated 
serine proteases such as NSPs (18,19). NSPs are 
synthetized as inactive zymogens containing a 
di-propeptide in the myeloblast/promyelocyte 
stage in the bone marrow (8,20). The proforms 
mature in this very early developmental stage, 
induced by CatC, through the cleavage of the N-
terminal di-propeptide.  The cleavage of the di-
propeptide by CatC results in a re-orientation 
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and remodeling of three surface loops within the 
activation domain of the protein and renders the 
S1 pocket of the active-site accessible to 
substrates (21). After processing, the active 
proteases are stored in cytoplasmic granules. 
CatC is synthetized as a 60-kDa single chain 
pro-form containing an exclusion domain, a 
propeptide, a heavy chain and a light chain (22). 
Pro-CatC which is a dimer, can be efficiently 
activated by proteolysis with CatL and S in vitro 
(22). The initial cleavages liberate the 
propeptide from the catalytic region. 
Subsequently, a further cleavage occurs 
between the heavy chain and the light chain 
which form a papain-like structure (22,23). X-
ray images of mature CatC structures revealed 
that the exclusion domain, the heavy chain and 
the light chain are held together by non-covalent 
interactions (17). Mature CatC is a tetramer 
formed by four identical monomers with their 
active site clefts fully solvent exposed. The 
presence of the exclusion domain blocks the 
active site beyond the S2 pocket and it is 
responsible for the diaminopeptidase activity of 
CatC (17,24). 
Loss of function mutations in the CatC gene 
(CTSC) results in Papillon-Lefèvre syndrome 
(PLS) (OMIM: 245000) (25,26), a rare 
autosomal recessive disease affecting 1 to 4 
persons per million (27,28). PLS involves an 
aggressive pre-pubertal periodontitis, leading to 
complete tooth loss in adolescence and 
palmoplantar keratoderma. More than 75 
mutations have been identified in PLS, with 
missense and nonsense mutations being the 
most frequent, but small deletions, insertions 
and splice site mutations have also been 
reported (29). The presumptive diagnosis of 
PLS can be made by clinical signs and 
symptoms, but confirmation requires CTSC 
sequencing. Analysis of urinary CatC in 
suspected patients can be also used as an early, 
simple and easy diagnostic test (30). Roberts et 
al. (31) demonstrated a variety of neutrophil 
defects in PLS patients, arising downstream of 
the failure to activate NSPs by CatC. These 
functional defects included failure to produce 
NETs, reduced chemotaxis and exaggerated 
cytokine and reactive oxygen species release. 
Pham et al. (19) also studied neutrophils from 
PLS patients and observed that the loss of CatC 
activity was associated with strong reduction in 
the proteolytic activity of NSPs. In addition, 
only very low protein amounts of PR3 and 
related NSPs were detected in PLS neutrophils 
(32-34). Thus, it is conceivable that mimicking 
the genetic situation in PLS neutrophils by 
pharmacological CatC inhibition in bone 
marrow precursor cells would provide an 
attractive therapeutic strategy in GPA to 
eliminate major PR3-related disease 
mechanisms, including the PR3-ANCA 
autoantigen itself. However, the effect of CatC 
inactivation on PR3 that is presented on the 
neutrophil surface where it becomes accessible 
to anti-PR3 antibodies is not known.  
In this work, we investigated the 
consequences of CatC inactivation on 
membrane-expression of PR3. First, we 
quantified the residual proteolytic activity of 
CatC and PR3 in white blood cell (WBC) 
lysates or isolated neutrophils from PLS 
patients. Second, we studied the membrane-
expression of PR3 on PLS neutrophils. Finally, 
we used a potent synthetic cell permeable nitrile 
inhibitor to evaluate the effect of 
pharmacological CatC inhibition on membrane-
PR3 expression in normal neutrophils generated 
from human CD34+ progenitor cells.  
 
Results 
CatC in blood cells from PLS patients 
Blood samples were collected from 13 PLS 
patients from European, Asian and African 
countries. PLS diagnosis was firmly established 
by genetic testing. These patients carried either 
premature stop codon, missense, nonsense or 
frameshift mutations in their CTSC (Table I). 
Blood from 8 additional patients with clinically 
suspected PLS was obtained. These patients 
showed typical symptoms of early-onset 
periodontitis and hyperkeratosis (Fig. 1A). 
WBC lysates from these patients and from 
healthy controls differed by their protein profile 
as observed by SDS-PAGE (Fig. 1B). CatC 
activity was assayed in peripheral WBC lysates 
or in purified neutrophils using a CatC-selective 
FRET substrate in the presence or absence of 
the selective nitrile CatC inhibitor (L)-Thi-(L)-
Phe-CN. Strong CatC activity was observed in 
control neutrophils and was completely 
abrogated by the specific CatC inhibitor. In 
contrast, we did not detect any CatC activity in 
samples, from genetically and clinically 
diagnosed PLS patients (Table I and Fig. 1C), 
nor any CatC protein in cell lysates from PLS 
patients using a specific anti-CatC Ab (Fig. 
1D). CatC activity and the CatC antigen were 
also absent in the urine of all PLS patients, 
unlike healthy controls (Fig. 1C, D). Thus, the 
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CatC deficiency of all 7 patients was confirmed 
as described in (30) and the mutations were 
identified by CTSC gene sequencing for some 
of these patients (supp.Fig. 2, Table I). Once 
CatC deficiency was clearly established, we 
studied the fate of PR3 in samples from PLS 
patients.    
 
Proteolytically active PR3 in blood cells from 
PLS patients 
 WB analysis of white blood cell or 
neutrophil lysates from PLS patients showed 
that low amounts of the PR3 antigen were still 
present in all PLS samples (Fig. 2A and 
supp.Fig. 4A). We checked that residual PR3 
was enzymatically active by incubating PLS 
samples with purified exogenous alpha-1-
proteinase inhibitor (1PI) (35) and observing 
the appearance of an additional ~75 kDa band 
corresponding to the irreversible complex 
between active PR3 and its inhibitor (Fig. 2B). 
In contrast to mature PR3, inactive pro-PR3 did 
not form any irreversible complex with 1PI 
(Fig. 3). We confirmed the presence of 
proteolytically active PR3 in permeabilized 
PLS neutrophils using an activity-based probe 
(Bt-PEG66-PYDA(O-C6H4-4-Cl)2) selective for 
PR3 and a fluorescent streptavidin derivative to 
reveal the formation of irreversible complexes 
(Fig. 2C). We also measured PR3 activity in 
supernatants of PLS cells activated with the 
A23187 calcium ionophore using ABZ-
VAD(nor)VADYQ-EDDnp as a substrate (Fig. 
2D). PR3 activity in PLS cell supernatants was 
about 1/20 that in controls cells and was almost 
totally abrogated by the PR3-specific inhibitor 
Bt-PYDAP(O-C6H4-4-Cl)2. We found that 10 to 
20 times more cell lysate proteins from PLS 
patients (2.5 to 5 µg/well) as compared to 
healthy controls (0.25 to 0.5 µg/well), were 
required to achieve similar PR3 activity values. 
Enzymatic activities in PLS cells and healthy 
control cells, measured on ABZ-
VAD(nor)VADYQ-EDDnp substrate, were 
almost completely inhibited by the PR3 
inhibitor (Fig. 4A, B, C). From these results, we 
estimated that blood cells of PLS patients 
contained from 0.5 to 4% of the PR3 activity in 
healthy controls cells (Fig. 4D and Table I). 
Marginal, but still detectable activity of CG was 
also observed in PLS samples using the 
appropriate selective FRET substrate (data not 
show). Next, we checked whether PR3 was 
present at the cell surface of PLS neutrophils.  
 
 Membrane surface expression of PR3 on 
PLS neutrophils 
Since the membrane expression of PR3 
depends on the activation status of neutrophils, 
we analyzed both quiescent neutrophils from 
two local patients (PLS 13 and PLS 14) 30 min 
after blood collection and neutrophils from 
foreign blood samples collected 24-72 h before 
the analysis and thus inevitably activated during 
shipping. As a control for the latter conditions, 
cells from either the parents or healthy 
individuals of the patient’s country-of-origin 
were collected at the same time. The flow 
cytometry analysis of PR3m using anti-PR3 
mAbs CLB12.8 showed that constitutive PR3m 
was present in significant amounts on quiescent 
PLS neutrophils and showed the typical 
bimodal pattern with low (PR3m(low)) and high 
(PR3m(high)) subsets. After cell activation with a 
calcium ionophore (A23187), we observed a 
single homogeneous PR3 population but no 
significant increase of the total amount of PR3m 
at the surface of PLS neutrophils whereas the 
bimodal pattern was conserved on control cells 
and the total amount of PR3 increased 
significantly (Fig. 5). We also found a single 
PR3m-presenting neutrophil population in PLS 
cells that were spontaneously and inevitably 
activated during transit (experiments with cells 
from 9 different PLS patients, Fig. 6 and 
supp.Fig. 4). The PR3 mean fluorescence 
intensity of these PLS neutrophils was 26 ± 8 % 
of the intensity found in controls. Thus, the 
absence of CatC in PLS patients affected 
constitutive PR3 expression at the surface of 
quiescent neutrophils only marginally but 
largely reduced the PR3 antigen exposure on the 
neutrophil surface of activated cells. Next, we 
assessed whether an early treatment of 
neutrophil precursor cells by a CatC inhibitor, 
would diminish PR3m expression, cellular PR3 
amount and proteolytic activity. 
 
Membrane surface expression of PR3 on 
neutrophils generated from human CD34+ 
progenitor cells in the presence of a CatC 
inhibitor 
We differentiated human CD34+ HSC 
isolated from umbilical cord blood into 
neutrophils in the presence or absence of a 
potent cell permeable cyclopropyl nitrile CatC 
inhibitor (IcatC) (32). Expression of the 
neutrophil surface markers CD16, CD66b, and 
CD11b was assessed by flow cytometry during 
the 10 day differentiation period and confirmed 
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neutrophil differentiation (Fig. 7A). At day 10, 
a typical bimodal PR3m expression pattern was 
observed by flow cytometry with a PR3m-
positive neutrophil subset of approximately 30-
40%. Importantly, CatC inhibition with the 
pharmacological compound IcatC did not affect 
neutrophil differentiation, but eliminated the 
bimodal PR3m expression pattern leaving only 
marginal PR3m amounts on the cell surface 
(Fig. 7A). The mean fluorescence intensity 
values for PR3m were reduced to 17±5 % by 
IcatC at day 10 (p<0.01). The analysis by 
immunoblotting of cell lysates of differentiated 
neutrophils, showed that the amount of PR3 
protein was strongly reduced after treatment 
with the CatC inhibitor (Fig. 7B) and that 
residual PR3 was enzymatically inactive (Fig. 
7C). Thus, inhibition of CatC in progenitor cells 
reduces both cellular and membrane PR3. This 
PR3 reduction was even stronger than that 
observed in neutrophils from PLS patients with 
genetic CatC deficiency.  
 
Discussion 
Neutrophils are key actors in the 
pathogenesis of ANCA-associated vasculitis 
(6). Neutrophil activation results in the 
production of NETs bearing PR3 (11). NETs-
associated PR3 is presented to dendritic cells 
triggering the production of PR3-ANCA by B-
cells (6). In addition, PR3 is the only NSP that 
is presented constitutively on the surface of 
circulating blood neutrophils and remains partly 
bound to the neutrophil surface following cell 
activation. These findings contribute to the 
important role of PR3 as the main target antigen 
in GPA and related vasculitis. Interaction of 
circulating PR3-ANCA with PR3m initiates the 
activation of circulating neutrophils and thus 
triggers necrotizing inflammation (6). Because 
neutrophils from PLS patients that lack CatC 
activity do not produce NETs (31,34) and 
contain only marginal levels of NSPs (19,33), it 
is reasonable to assume that blocking NETosis 
and/or eliminating PR3 by interfering with 
CatC activity pharmacologically would 
ultimately reduce vascular inflammation. Thus, 
in vivo inhibition of CatC by a synthetic cell 
permeable inhibitor that mimicks the conditions 
observed in PLS patients, could have 
therapeutic potential by reducing PR3-ANCA 
production, neutrophil activation, endothelial 
cell necrosis and inflammation. We have 
compared here the effects of genetic and 
pharmacological CatC inactivation on the fate 
of soluble PR3 and PR3m.     
Because CatC is pathologically inactivated 
by gene mutations in PLS patients, we first used 
WBC lysates from 21 PLS, 17 of these patients 
with established missense, frameshift or 
nonsense mutations, to investigate the fate of 
cellular and membrane PR3. As expected, we 
observed neither CatC activity nor 
immunoreactive CatC protein in PLS cell 
lysates irrespective of the underlying CatC 
mutations. It may be surprising that mutated 
CatC with a missense mutation was neither 
detected in cell lysates nor in the urine of PLS 
patients (30). However, our observation 
corroborates a previous report from the 
literature (34) and gives support to the 
conclusion that missense mutations in the CTSC 
gene abrogates the constitutive secretion of 
CatC and triggers its degradation in intra- or 
extra cellular compartments.  
The loss of CatC activity in PLS patients was 
associated with a severe reduction in the activity 
and the amounts of NSPs (19,32-34). We also 
found that PR3 activity in PLS WBC lysates 
was strongly lowered to 1-4% of that in control 
lysates, but was still detectable. We employed 
several approaches to ensure that the measured 
proteolytic activity was indeed due to PR3. We 
used a highly sensitive and specific PR3 
substrate, a specific PR3 inhibitor that totally 
abrogated the enzymatic activity, and finally, a 
selective PR3 activity-based probe to detect 
active PR3 in PLS neutrophils. The results 
clearly confirmed the presence of residual 
active PR3 in PLS neutrophils, suggesting that 
CatC is the main, but not the sole protease 
involved in the activation of pro-NSPs. This 
observation is consistent with data from Roberts 
et al. who demonstrated the presence of some 
LL37 in stimulated neutrophil supernatants 
from PLS patients, LL37 being a product of 
PR3 cleavage of human cathelicidin 18 (31). 
We then investigated whether or not the 
unprocessed pro-PR3 was still present in PLS 
cell lysates. For this purpose, we exploited the 
property of 1PI to form irreversible complexes 
with proteolytically active PR3 but not with its 
proform. Following incubation of PLS cell 
lysates with 1PI, almost all immunoreactive 
PR3 formed irreversible complexes with the 
inhibitor suggesting that only residual mature 
PR3 was present in cell lysates. Having ensured 
that the absence of the pro-PR3 was not due to 
the cell lysis procedure, we conclude that most 
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of pro-PR3 was degraded very early in PLS 
neutrophil precursors. Our data are compatible 
with the notion that a small amount of the pro-
PR3 can be early processed into an active 
protease by one or several aminopeptidase(s) 
other than CatC. These enzymes remain to be 
identified. 
Human PR3 is expressed constitutively in a 
bimodal manner with two populations of 
neutrophils presenting either high (PR3m(high)) 
or low (PR3m(low)) amounts of the protease on 
their surface (36,37). The level of PR3m on 
resting neutrophils and the percentage of PR3m 
expressing neutrophils is stable over time for a 
given individual (5,37). In spite of the low PR3 
level in PLS cell lysates, we observed that PR3m 
was present at the surface of resting PLS 
neutrophils showing a typical bimodal 
distribution similar to control neutrophils. This 
observation suggests that the expression of 
constitutive PR3m on resting neutrophils is 
independent of intracellular PR3 levels and 
remains stable even when CatC is inactive. 
Activating cells from PLS patients with the 
calcium ionophore A23187 resulted in a PR3 
increase on the neutrophil surface but this 
increase was significantly smaller than that 
observed in control cells. Thus, the genetic 
inactivation of CatC results in a dramatic 
decrease of PR3 within intracellular granules 
but does not interfere with the constitutive 
expression of proteolytically inactive PR3 
(38,39) at the surface of quiescent PLS 
neutrophils. This data suggests a different 
intracellular storage site and a different 
intracellular pathway for constitutive and 
induced PR3m. Unexpectedly, and in contrast to 
control cells, no bimodal PR3m expression 
pattern was observed in activated PLS cells. 
This observation was made in both 
spontaneously activated cells during shipping 
and with a pharmacological compound. We 
have no obvious explanation for this finding at 
the moment.  
We showed previously that a two-step 
amplification/differentiation protocol of human 
CD34+ hematopoietic stem cells obtained from 
umbilical cord blood results in differentiated 
neutrophils (40). We used this model system to 
investigate the production and the fate of PR3 
in the presence of a CatC nitrile inhibitor, IcatC 
(23). A subset of PR3m-positive cells was 
detectable by flow cytometry at day10 whereas 
a second cell subset remained negative, 
consistent with a bimodal expression typically 
seen with blood neutrophils. Differentiation of 
CD34+ HSC into neutrophils in the presence of 
the CatC inhibitor IcatC did not alter the 
expression of the neutrophil surface markers 
CD16b, CD66b and CD11b but resulted in 
strong reduction of intracellular and membrane 
PR3. Pharmacological CatC inhibition 
eliminated PR3 from normal neutrophils more 
effectively than mutated CatC in PLS 
neutrophils. It is conceivable that additional 
aminopeptidases exist in blood neutrophils that 
were absent in CD34+ HCS-derived neutrophils 
or that the potent IcatC inhibitor inhibited CatC 
together with additional proteases involved in 
the activation of the pro-PR3. Our current 
observations in PLS cells and our recent work 
reporting the complete disappearance of HNE 
in bone marrow cells from healthy donors 
pulse-chased in presence of IcatC supports the 
latter hypothesis (32).  
To conclude, we showed here that CatC is 
the major but not the unique pro-PR3 
processing protease in neutrophils since low 
amounts of proteolytically active PR3 are still 
present in neutrophils of CatC deficient 
individuals. Treating CD34+ hematopoietic 
stem cells with the CatC inhibitor ICatC 
resulted in an almost total absence of 
intracellular PR3 and PR3m in stem cells-
derived neutrophils. The elimination of the 
PR3-ANCA target antigen supports the notion 
that pharmacological CatC inhibition provides 
an alternative therapeutic strategy for reducing 
neutrophil-mediated vascular inflammation in 
auto-immune vasculitis. We previously showed 
that a prolonged IcatC administration in the 
macaque resulted in an almost complete 
elimination of PR3 and NE (32). Unlike humans 
however, macaques do not display constitutive 
PR3 at the surface of their circulating 
neutrophils and therefore cannot be used as a 
relevant model of GPA. Only clinical studies in 
GPA patients will answer the question whether 
or not a CatC inhibitor may function as a PR3-
ANCA antigen suppressor.  
 
Experimental Procedures 
Blood collection- Blood samples were 
collected from 21 PLS patients from European 
countries (Germany, the UK, Italy, France, 
Hungary), from Asian countries (India, Saudi 
Arabia) and from Egypt. The 13 healthy 
volunteers were from France, India, Italy, Saudi 
Arabia and Egypt. 2-15 mL peripheral blood 
7 
 
samples from healthy control donors and 
patients with PLS were collected into EDTA K2 
preservative tubes by peripheral venipuncture. 
Samples were taken giving informed consent. 
Red blood cells lysis took place with 0.1 mM 
EDTA, 10 mM KHCO3, 150 mM NH4Cl and 
white cells pelleted with centrifugation for 5 
min at 400 x g. 
 
Blood neutrophil purification- Neutrophils 
were isolated by Percoll density centrifugation, 
employing two discontinuous gradients of 
1.079 and 1.098, and purified by erythrocyte 
lysis (0.83% NH4Cl containing 1% KHCO3, 
0.04% EDTA, and 0.25% BSA) previously 
described (31). Cells were then re-suspended in 
gPBS (phosphate-buffered saline) (1 mM 
glucose) and cations (1 mM MgCl2, 1.5 mM 
CaCl2). Cell viability was determined by 
Trypan blue dye exclusion (typically 98%) and 
cell purity by cytospin.  
 
Differentiation of CD34+ hematopoietic 
stem cells from umbilical cord blood into 
neutrophils- Umbilical cord blood samples 
were taken giving informed consent. 
Mononuclear cells were obtained from anti-
coagulated cord blood by centrifugation over a 
LSM1077 (PAA, Pasching, Austria) gradient at 
800 x g for 20 min. Cells were washed and 
stained using the CD34+ progenitor isolation kit 
(Miltenyi, Bergisch-Gladbach, Germany) and 
sorted according to the manufacturer’s 
instructions. CD34+ cells were cultivated in 
stem span serum free medium (Cell Systems, St. 
Katharinen, Germany) supplemented with 
Penicillin/Streptomycin, 100 ng/mL SCF, 20 
ng/ml TPO and 50 ng/mL FLT3-L (Peprotech, 
London, UK) for expansion. Neutrophil 
differentiation was performed in RPMI with 
10% FCS, 10 ng/mL G-CSF (Peprotech), and 
either DMSO control or 1 µM IcatC. Medium 
was changed every other day. We PR3-
phenotyped the neonatal neutrophils obtained 
from the freshly harvested umbilical cords by 
flow cytometry prior to the CD34+ HSC 
isolation. We selected only cord blood where 
the neonatal neutrophils showed a clear bimodal 
membrane PR3 pattern.  
 
Measurement of protease activities in cell 
lysates- WBC, purified blood neutrophils, 
CD34+ or neutrophil-differentiated CD34+ HSC 
were lysed in 50 mM HEPES buffer, 750 mM 
NaCl, 0.05% NP-40, pH 7.4. Soluble fractions 
were separated from cell debris by 
centrifugation at 10,000 x g for 10 min. Soluble 
fractions were concentrated by ultrafiltration 
(Vivaspin (filtration threshold 10 kDa)) in some 
experiments. Proteins were assayed with a 
bicinchoninic acid assay (BCA) (Thermo Fisher 
Scientific, Villebon sur Yvette, France). 
The CatC activity in cell lysates was 
measured spectrofluorometrically (Spectra Max 
Gemini EM) at 420 nm with or without the 
nitrile inhibitor (L)-Thi-(L)-Phe-CN (23) (1 µM 
final, 20 min incubation at 37°C) using Thi-
Ala(Mca)-Ser-Gly-Tyr(3-NO2)-NH2 (41) (20 
µM final) as selective fluorescence resonance 
energy transfer (FRET) substrate in 50 mM 
sodium acetate, 30 mM NaCl, 1 mM EDTA, 2 
mM DTT, pH 5.5 at 37°C. Mature human CatC 
was used as control (Unizyme Laboratories, 
Hørsholm, Denmark). 
The PR3 activity in cell lysates was 
measured at 420 nm with or without the PR3 
inhibitor Ac-PYDAP(O-C6H6-4-Cl)2 (42) (0.5 
µM final, 20 min incubation at 37°C) using 
ABZ-VAD(nor)VADYQ-EDDnp (20 µM final, 
Genecust, Dudelange, Luxembourg) as a 
substrate in 50 mM HEPES buffer, 750 mM 
NaCl, 0.05% NP40, pH 7.4 at 37°C. The CatG 
activity was measured at 420 nm in 50 mM 
HEPES buffer, 100 mM NaCl, 0.05% NP-40, 
pH 7.4 at 37°C, in the presence or not of 2 µM 
antichymotrypsin, using ABZ-TPFSGQ-
EDDnp (43) (20 µM final, Genecust, 
Dudelange, Luxembourg) as a substrate.  
 
Western blotting- The pellet of purified 
blood neutrophils and WBC were directly lysed 
in SDS sample buffer (25 mM Tris (pH 7), 10% 
glycerol, 1% SDS, 10% 2-mercaptoethanol). 
The pellet of CD34+ HSC or neutrophil-
differentiated CD34+ HSC were lysed in sample 
buffer (20 mM Tris (pH 8,8), 138 mM NaCl, 
10% glycerol, 2 mM EDTA, 1%Triton-X-100, 
1% NP-40 and protease inhibitor mix). The total 
protein concentration has been determined by 
the BCA (Thermo Fisher Scientific, Villebon 
sur Yvette, France) or Bradford (Bio-Rad, 
Hercules, USA) assay.  
The proteins were separated on 10% or 12% 
SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing and denaturing 
conditions (7-50 µg of protein per lane). They 
were transferred to a nitrocellulose (Hybond)-
Enhanced chemiluminescence (ECL) 
membrane at 4°C. Free sites on the membranes 
were blocked by incubation with 5% nonfat 
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dried milk in PBS, 0.1% Tween for 90 min at 
room temperature (RT). They were washed 
twice with PBS, Tween 0.1% and incubated 
overnight with a primary antibody (murine anti-
human CatC antibody (Ab) directed against the 
heavy chain of CatC (Ab1, sc-747590) (1:1000, 
Santa Cruz  Biotechnology, Heidelberg, 
Germany (30)), goat anti-human CatC (Ab2, 
EB11824) directed against the propeptide 
(1:1000, Everest Biotech, Oxfordshire, UK 
(30)), rabbit anti-PR3 Ab (ab133613) (1:1000,  
Abcam, Cambridge, UK) (23)), rabbit anti-
myeloperoxydase (MPO) heavy chain (1:500, 
sc-16128-R, Santa Cruz Biotechnology, 
Heidelberg, Germany) followed by a specific 
secondary antibody (a sheep anti-mouse IgG 
secondary antibody (1:10000, A5906, Sigma-
Aldrich), a goat anti-rabbit IgG secondary 
antibody (1:10000, A9169, Sigma-Aldrich)). 
Membranes were washed (3 x 10 min) with 
PBS, 0.1% Tween and the detection was 
performed by ECL system. 
 
Flow cytometry- WBC from PLS patients or 
healthy controls were resuspended in PBS and 
a blocking step was performed with 5% bovine 
serum albumin (BSA), 2.5 mM EDTA in PBS 
for 15 min at 4°C. Or WBC were fixed with 2% 
paraformaldehyde and permeabilized with 
0,5% Triton-X 100 in PBS and non-specific 
binding sites were blocked with 5% BSA. Flow 
cytometry analyses were performed using a 
MACSQuant analyzer (Miltenyi Biotec, 
Bergisch-Gladbach, Germany) and VenturiOne 
software (Applied Cytometry, Sheffield, United 
Kingdom). These analyses were performed 
using the following Abs: V450-conjugated 
CD14 (MφP9, 1:200), PE-conjugated CD3 
(HIT3a, 1:200), PE-Cy™-conjugated CD11b 
(M1/70, 1:100), APC-conjugated CD16 (3G8, 
1:200), APC-H7-conjugated CD45 (2D1, 
1:200) (BD Biosciences, Le Pont de Claix, 
France), PerCP-Vio700-conjugated CD15 
(VIMC6, 1:100) (Miltenyi Biotec, Bergisch-
Gladbach, Germany), FITC-conjugated IgG1 
(679.1Mc7, 1:20) (Dako, Hamburg, Germany), 
FITC-conjugated CD16 (DJ130c, 1:20) (Dako, 
Hamburg, Germany), FITC-conjugated CD18 
(/E4, 1:20) (Beckmann Coulter, Krefeld, 
Germany), FITC-conjugated CD66b (80H3, 
1:20) (Beckmann Coulter, Krefeld, Germany). 
The PR3 was labelled with the primary mouse 
mAb CLB12.8 (1:50) (Sanquin, Amsterdam, 
Netherlands) and the secondary antibody FITC-
conjugated anti-mouse IgG (sc-2010, 1:100) 
(Santa Cruz Biotechnology, Heidelberg, 
Germany) or the secondary antibody FITC-
conjugated IgG1 Fab2 (DAK-GQ1, 5µg/mL) 
(Dako, Hamburg, Germany). Dead cells were 
stained with Viobility 405/520 Fixable Dye 
(1:200) (Miltenyi Biotec, Bergisch-Gladbach, 
Germany). The gating strategies used are 
described in supp.Fig. 1. The compensation 
was performed using VenturiOne software.  
 
Genetic analysis- 
Extraction of genomic DNA (salting out 
procedure): Peripheral blood samples were 
obtained from the patients and both parents (if 
available) after informed consent had been 
given according to NRC guidelines. Genomic 
DNAs were prepared as previously described 
by (44) with some additional modifications 
described by (45). 
 
PCR amplification of CTSC gene exons: For 
analysis of CTSC mutations, eight different 
specific amplifications using CTSC gene 
specific primers carried out on the genomic 
DNA according to Toomes et al., (26), except 
for the newly developed primer pairs for exons 
1 and the 5´ half of exon 7. 
 
 
 
PCR was performed in a final volume of 25 
μL containing ~ 100 ng genomic DNA, MgCl2 
(1.5 mM), dNTP mixture (0.2 mM), Taq DNA 
polymerase (2 U/μL), and 10 μM of each primer 
(MWG-BIOtech, Ebersberg, Germany). 
The amplification conditions were as 
follows: 2 min at 95°C for one cycle, followed 
by 35 cycles of 30 s at 94°C, 30 s at the 
annealing temperature of the primers (53°C for 
exons 7a and 7b, 54.5°C for exon2, 55.2°C for 
exons 1 and 6, 56.6°C for exon 3, 57.2°C for 
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exon 4 and 58°C for exon 5), and 1 minute at 
72°C in a thermal cycler (Agilent Technologies 
SureCycler 8800) (46). Five microliters aliquots 
of the PCR products were analyzed by 2% 
agarose gel electrophoresis. 
 
Mutation analysis: PCR products were purified 
using the QIA Quick PCR Purification kit 
(Qiagene) followed by bidirectional sequenced 
using the ABI Prism Big Dye Terminator v3.1 
Cycle Sequencing kit (Applied Biosystems) and 
the sequencing reaction products were 
separated on an ABI Prism 310 Genetic 
Analyzer (Applied Biosystems). Alignment of 
sequenced results used NCBI genomic 
sequence NG_008365.1 and reference cDNA 
sequence NM_000348.3 for result 
interpretation. 
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FOOTNOTES 
The abbreviations used are: 1PI, alpha-1-proteinase inhibitor; Ab, antibody; ABZ, ortho-aminobenzoic 
acid; ANCA, anti-neutrophil cytoplasmic autoantibody; BCA, bicinchoninic acid; Bt, biotin; CatC, 
cathepsin C; CG; cathepsin G; DMSO, dimethyl sulfoxide; ECL, enhanced chemiluminescence; 
EDDnp, N-(2.4-dinitrophenyl)ethylenediamine; FRET, fluorescence resonance energy transfer; GPA, 
granulomatosis with polyangiitis; HBSS, Hank’s balanced salt buffer; HNE, human neutrophil elastase; 
HSC, hematopoietic stem cell; MPO, myeloperoxidase; NSP; neutrophil serine protease; PBS, 
phosphate-buffered saline; PEG, polyethlene glycol; PLS, Papillon-Lefèvre syndrome; PMN, 
polymorphonuclear neutrophil; PR3, proteinase 3; PR3m, membrane-bound PR3; RT, room temperature; 
SDS-PAGE, sodium dodecyl sulfate polyacrylamide gel electrophoresis; WBC, white blood. 
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TABLE I 
 Patient’s informations 
 
 
#CatC mutations identified in this work. ‡Identified by Professor N.S Thakkar, Academic Unit of 
Medical Genetics, University of Manchester, Manchester, UK. The mutation carried by patients 13 and 
14 were determined as in Hamon et al., 2016 (30) 
a Ragunatha et al., 2015 (47) 
Patients Age 
(Years) 
Gender Ethnicity CatC mutation CatC activity PR3 activity 
(%) 
1 18 M Indian 
(India) 
c.912C>A (p.Y304X)a 
nonsense 
Not detectable 4.3 
2 12 F Egyptian  
(Egypte) 
c.711G>A (p.W237X)b 
nonsense 
Not detectable 3.9* 
3 8 F Turkish 
(France) 
c.628C>T (p.Arg210X)c 
c.1286G>A (p.Trp429X) 
Compound heterozygous 
nonsense 
Not detectable 1.8 
4 44 F Italian 
(Italy) 
c.1141delC 
(p.L381fsX393)d 
frameshift 
Not detectable 1.8 
5 20 M Saudi Arabian 
(Saudi Arabia) 
c.815G>C (p.R272P)e 
missense 
Not detectable 2.1* 
6 27 M Saudi Arabian 
(Saudi Arabia) 
c.815G>C (p.R272P)e 
missense 
Not detectable Not tested 
7 5 M Pakistanian 
(UK) 
c.815G>C (p.R272P)‡ 
missense 
Not detectable 0.75 
8 4 M Pakistanian 
(UK) 
c.815G>C (p.R272P)‡ 
missense 
Not detectable 1.8** 
9 16 M Pakistanian 
(UK) 
c.815G>C (p.R272P)‡ 
missense 
Not detectable 0.63** 
10 11 M Pakistanian 
(UK) 
c.815G>C (p.R272P)‡ 
missense 
Not detectable 0.50 
11 16 F Pakistanian 
(UK) 
c.815G>C (p.R272P)‡ 
missense 
Not detectable 0.58** 
12 14 M British 
caucasian 
(UK) 
c.415G>A (p.G139R)‡ 
c.1280A>C (p.N427T) 
Compound heterozygous 
missense 
Not detectable 0.50 
13 17 F Moroccan 
(France) 
c.757G>A (p.A253I)
#
 
missense 
Not detectable 1.7 
14 11 M Moroccan 
(France) 
c.757G>A (p.A253I)
#
 
missense 
Not detectable 2.0 
15 13 F Egyptian 
(Egypte)  
Not identified Not detectable 1.1** 
16 7 M Nubian 
(Egypte) 
c.1015C>T (p.R339C)
#
 
missense 
Not detectable 0.8* 
17 12 F Nubian 
(Egypte) 
c.1015C>T (p.R339C) 
suspected 
Not detectable 0.9* 
18 12 M Egyptian 
(Egypte)   
Not identified Not detectable 1.3* 
19 12 M Egyptian 
(Egypte)   
a splice site mutation in 
intron 3 IVS3-1G  A  
Not detectable 1.5* 
20 17 M Egyptian 
(Egypte) 
Not identified Not detectable 2.1 
21 13 M Egyptian 
(Egypte) 
Not identified Not detectable 2.5 
17 
 
b Soliman et al., 2015 (48) 
c Martinho et al., 2017 (49) 
d Bullon et al., 2014 (50) 
e  Hamon et al., 2016 (30) 
  
Patient 13 and patient 14 are siblings 
Patient 16 and patient 17 are siblings 
Patient 2 and patient 15 are cousins  
 
* Purified neutrophil lysates 
** WBC lysates 
 The Nubian ethnicity people are also North African (residing upper Egypt at the borders with Sudan) 
but they have characteristic features of dark skin and African facial features.  
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Figure 1. CatC in biological samples of PLS patients. (A) Characteristic dental and palmoplantar 
features of PLS (patient 18). Photos show early loss of teeth and hyperkeratosis of the palms and soles. 
(B) Neutrophil and WBC lysates from PLS patients and from healthy controls, lysed in 50 mM HEPES 
buffer, 750 mM NaCl, 0.05% NP40, pH 7.4 during 5 min at RT and analyzed by SDS-PAGE (12%) 
/silver staining under reducing conditions (10 µg/lane) strongly differ by their protein profile. (C) 
Measurement of CatC activity in WBC lysates (10 µg of protein) (Top) and concentrated urines (Bottom) 
in the presence or not of a selective CatC inhibitor. The residual proteolytic activity was not inhibited 
by the CatC inhibitor which demonstrates the absence of CatC activity in PLS samples. (D) Western-
blot analysis of WBC lysates (10 µg of protein) and concentrated urines of PLS samples and controls 
using anti-CatC antibodies shows the absence of the CatC heavy chain in all PLS samples. The urines 
were collected and analyzed as in Hamon et al., 2016 (30). C: control, P: PLS patient, FU: fluorescence 
unit. 
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Figure 2. Active PR3 in PLS blood samples. (A) Western-blotting of WBC lysates (10 µg of protein) 
from PLS and healthy controls using anti-PR3 antibodies: low amounts of PR3 are present in PLS 
samples. (B) Western-blotting of PLS white blood cells lysates (10 µg of protein) incubated with 1PI 
(5 µM) in 50 mM HEPES buffer, 750 mM NaCl, 0.05% NP40, pH 7.4 during 3 h at 37°C. The de novo 
formation of irreversible 1PI-PR3 complexes of about 75 kDa reveals that PR3 is proteolytically active 
in spite of the absence of active CatC. (C) (Top) Flow cytometry analysis of the expression of PR3 in 
permeabilized PLS neutrophils. Using anti-PR3 antibodies, a lesser fluorescence is observed in 
permeabilized neutrophils from two PLS siblings (P13 and P14) (red) as compared with their mother 
used here as a control (blue). The grey peak corresponds to the isotype control. (Bottom). The use of 
PR3 activity probe Biotin-PEG66-PYDA(O-C6H4-4-Cl)2 as in Guarino et al., (42) shows that the residual 
PLS PR3 is enzymatically active. The gray peek indicates the fluorescence of permeabilized neutrophils 
incubated with streptavidin-Alexa Fluor488. The dotted gray peak corresponds to the 
(auto)fluorescence of permeabilized neutrophils. (D) PR3 activity in supernatants of calcium ionophore 
A23187 (Sigma-Aldrich, St. Quentin Fallavier, France) activated WBC in the presence or absence of 
the specific PR3 inhibitor Ac-PYDA(O-C6H4-4-Cl)2. PR3 activity in PLS cell supernatants is about 1/20 
of that in control cells and is almost totally inhibited in the presence of the selective PR3 inhibitor. C: 
control, Inh: inhibitor, P: PLS patient, FU: fluorescence unit. 
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Figure 3. Irreversible complex formation analysis of pro-PR3 and pro-HNE with α1PI. (A) 
Recombinant pro-PR3 (0.8 µM), mature PR3 (0.8 µM) produced and purified as in (51) and (B) pro-
HNE (1 µM), HNE (3 µM) produced and purified as in (52) were incubated with recombinant α1PI (5 
µM) in 50 mM HEPES buffer, 750 mM NaCl, 0.05% NP40, pH 7.4 at 37°C, and then analyzed by SDS-
PAGE and silver staining. The formation of stable covalent complexes of about 75 kDa was observed 
with pro-HNE but not with pro-PR3 as visualized in 15% SDS-PAGE under reducing and denaturing 
conditions. 
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Figure 4. PR3 activity in PLS blood samples. PR3 activities in purified neutrophil (A, Left) or in WBC 
lysates (A, Right). PR3 activities were measured with the selective substrate ABZ-VAD(nor)VADYQ-
EDDnp. Samples were also incubated with the selective PR3 inhibitor Bt-PYDA(O-C6H4-4-Cl)2 to 
distinguish PR3 activity and nonspecific signal (B,C). Low levels of active PR3 were found in PLS cell 
lysates (5µg) compared to control cell lysates (0,25µg). (D) Percentage of PR3 activity in neutrophils 
and whole blood samples. We calculated the percentage of PR3 activity in purified neutrophils and in 
WBC of PLS patients (n=20) compared to healthy controls cells (n=11). We estimated that PLS cells 
contained 0.5 to 4 % of PR3 activities compared to healthy cells. Similar results were found in three 
independent experiments. C: control, Inh: inhibitor, P: PLS patient, FU: fluorescence unit. 
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Figure 5. Membrane expression of PR3 on quiescent and chemically activated PLS neutrophils. WBC 
from PLS siblings (local patients P13 and P14) and their mother were activated using calcium ionophore 
(A23187) 30 min after blood collection. Both viable quiescent PLS (red dotted line) and control (blue 
dotted line) cells showed expression of PR3 on their surface. After chemical activation (continuous 
lines), membrane PR3 was largely increased on control cells while PR3 on PLS neutrophils was almost 
the same as on quiescent cells. We used Viobility 405/452 Fixable Dye to discriminate between live and 
apoptotic/dead cells. Flow cytometry revealed 81±5% viable neutrophils in all samples. No statistically 
significant difference between quiescent and activated neutrophils was observed (t test). P: PLS patient. 
Numbers indicate mean fluorescent intensity values.  
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Figure 6. Membrane expression of PR3 on PLS neutrophils activated during transportation. PR3 
expression on spontaneously activated neutrophils was investigated by flow cytometry.  Control of cell 
activation was made using an anti-CD16 and an anti-CD11b antibody. Control cells were from parents 
or from randomly selected blood donors in the local environment of the patient. C: control, P: PLS 
patient. Similar results were obtained with cells from 9 other PLS patients.  
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Figure 7. Effect of pharmacological CatC inhibition on PR3 expression and proteolytic activity in 
neutrophil-differentiated CD34+ HSC. CD34+ HSC were differentiated over 10 days into neutrophils in 
the presence of DMSO buffer control (Bu, blue) or 1 µM of the CatC inhibitor (IcatC, red). (A) Flow 
cytometry indicates that differentiating cells acquired the typical neutrophil surface markers CD16, 
CD66b, and CD11b, together with a bimodal membrane PR3 phenotype. Color lines represent staining 
with the specific antibodies and dotted lines represent the corresponding isotype control. A 
representative of five independent differentiation experiments is shown. (B) PR3 protein was assessed 
in cell lysates (7.0 µg/lane) by immunoblotting at the indicated time points using a specific anti-PR3 
antibody. PR3 protein was strongly induced during CD34+ HSC differentiation and this effect was 
significantly reduced with IcatC. A representative western blot and the densitometric analysis from five 
25 
 
independent differentiation experiments is shown. Bars indicate mean ± SEM value of each condition 
and asterisks the p-value of t test (p <0.05, *; p<0.01, **).  (C) Proteolytic PR3 activity was assessed in 
cell lysates (2.5 µg protein) at the indicated time points using the PR3-specific FRET substrate ABZ-
VAD(nor)VADYQ-EDDnp. Representative PR3 substrate conversion curves from one of five 
independent differentiation experiments are depicted together with the corresponding statistics for the 
mean Vmax values ± SEM (n=5 independent differentiation experiments). The data show a complete 
loss of proteolytic PR3 activity with CatC inhibition. Isolated normal blood neutrophils (PMN) served 
as a positive and endothelial cell line as a negative control (neg ctrl). Asterisks indicate the p-value of t 
test (p <0.05, *; p<0.01, **). 
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Supp.Figure 1. Gating strategies. WBC were isolated from EDTA-whole blood by red blood cells lysis. 
T cells and dead cells were excluded using anti-CD3 Ab and Viobility 405/520 Fixable Dye. The 
remaining cells were analyzed for the expression of CD15, a neutrophil marker. The percentages of cells 
in each of the specified gates are indicated.   
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Supp.Figure 2. Pedigrees and genetic analysis of PLS patients. (A) Pedigree chart for family 1 and 
family 2. Multigenerational pedigree of family 1 showing two affected siblings (P16 and P17) of 
consanguineous parents. Family tree 2 shows one affected son of consanguineous parents. (B) CTSC 
gene exon 7a sequence, the upper chromatogram showing the homozygous missense mutation 
1015C→T (R339C) in patient 16 (P16), the middle chromatogram shows the heterozygous mutation of 
the healthy mother and the lower chromatogram shows the normal sequence of a unrelated individual. 
(C) CTSC gene exon 3 sequence. DNA sequence of exon 3 showing the homozygous missense mutation 
1015C→T (R339C) in patient 19 (P19), the middle chromatogram shows the heterozygous genotype of 
the healthy mother and the lower chromatogram shows the normal sequence of an unrelated individual. 
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Supp.Figure 3. PR3 in PLS blood samples. (A) Western-blotting of WBC lysates (10 µg of protein) 
from PLS and healthy controls using a primary anti-PR3 Ab and a secondary HRP-labelled Ab. Amounts 
of PR3 were found to be highly reduced in PLS cells compared to healthy controls or parents. (B) 
Western-blotting of WBC lysates (10 µg of protein) from PLS and healthy controls developed with the 
HRP-labelled secondary antibody. No unspecific Ab binding was observed. We used an anti-MPO 
antibody as a positive control for the unaltered levels of MPO. C: control, P: PLS patient, M: mother, F, 
father. 
  
29 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supp.Figure 4. Membrane expression of PR3 on PLS neutrophils activated during transportation. (A) 
PR3 expression on spontaneously activated neutrophils was investigated by flow cytometry. Controls 
were randomly selected in the local environment of the patient. (B) Mean fluorescence intensity values 
for PR3m on PLS and healthy neutrophils. Bar indicates mean ± SEM value of each condition and 
asterisks the p-value of t test (p< 0.001,***). C: control (n=3), P: PLS patient (n=7).  
 
